Investigation of the frequency of reversible hyperbilirubinemia in newborns hospitalized in affiliated hospitals of Azad University, Tehran Medical Branch

Sahafian, Maryam; Mohammadnuri, Marjan; Shojaei, Parisa; Hassani, Parvaneh

Volume 13, Issue 4 (12-2025) jmsthums 2025, 13(4): 17-25 | Back to browse issues page

Mendeley

Zotero

RefWorks

Sahafian M, Mohammadnuri M, Shojaei P, Hassani P. Investigation of the frequency of reversible hyperbilirubinemia in newborns hospitalized in affiliated hospitals of Azad University, Tehran Medical Branch. jmsthums 2025; 13 (4) :17-25
URL: http://jms.thums.ac.ir/article-1-1368-en.html

Investigation of the frequency of reversible hyperbilirubinemia in newborns hospitalized in affiliated hospitals of Azad University, Tehran Medical Branch

Maryam Sahafian¹

, Marjan Mohammadnuri²

, Parisa Shojaei³

, Parvaneh Hassani⁴

1- Faculty of medicine, TeMS.C., Islamic Azad University, Tehran, Iran
2- Department of pediatric, faculty of Medicine, TeMS.C., Islamic Azad University, Tehran, Iran
3- Department of Community Medicine, TeMS.C., Islamic Azad University, Tehran, Iran
4- Department of Radiology, School of Medicine, University of Maryland, Baltimore, Maryland, USA

Abstract: (26 Views)

Background & Aim: Hyperbilirubinemia is a common and critical neonatal issue, affecting 60% of term and 80% of preterm infants in the first week of life. Recurrent hyperbilirubinemia can lead to serious complications like bilirubin toxicity, encephalopathy, and rehospitalization, which increase healthcare costs.
Methods: This descriptive-analytical study reviewed medical records of 144 neonates readmitted for hyperbilirubinemia in Tehran Azad University hospitals (2016–2020). Variables analyzed included maternal age, neonate gender, gestational age, birth weight, exclusive breastfeeding, blood group and Rh incompatibility, sepsis, and hemolysis.
Results: It was revealed that 18.1% of neonates had recurrent hyperbilirubinemia, with no significant association with gender (p=0.140) or maternal age (p=0.494). Significant relationships were found between recurrent hyperbilirubinemia and blood group and Rh incompatibility (p<0.001), sepsis (p<0.001), hemolysis (p<0.001), birth weight (p<0.001), gestational age (p=0.035), and exclusive breastfeeding (p=0.002).
Conclusion: The study highlights that 18.1% of neonates experienced recurrent hyperbilirubinemia, emphasizing its association with factors like feeding type, blood group incompatibility, and neonatal health conditions. However, maternal age and gender were not significant predictors. These findings underscore the need for early detection and targeted interventions to prevent complications associated with hyperbilirubinemia.

Keywords: Reversible hyperbilirubinemia, Infant, Hemolysis, Sepsis

Full-Text [PDF 263 kb] (37 Downloads)

Type of Study: Research | Subject: General
Received: 2025/07/26 | Accepted: 2025/11/22 | Published: 2026/02/9

References

1. Metcalfe A, Mathai M, Liu S, Leon JA, Joseph K. Proportion of neonatal readmission attributed to length of stay for childbirth: a population-based cohort study. BMJ open. 2016;6(9):e012007. [DOI:10.1136/bmjopen-2016-012007]

2. Porter ML, Dennis MBL. Hyperbilirubinemia in the term newborn. American family physician. 2002;65(4):599.

3. Lazar L, Litwin A, Merlob P. Phototherapy for neonatal nonhemolytic hyperbilirubinemia: analysis of rebound and indications for discontinuing therapy. Clinical pediatrics. 1993;32(5):264-7. [DOI:10.1177/000992289303200502]

4. Hamad IA, Chalabi DA. Rebound hyperbilirubinemia in a sample of newborns with jaundice. Journal of Kurdistan Board of Medical Specialties. 2019;5(2). [DOI:10.56056/amj.2019.108]

5. Kair LR, Phillipi CA. Simplifying hyperbilirubinemia risk estimation. Pediatrics. 2021;147|(5). [DOI:10.1542/peds.2020-046284]

6. Okumura A, Ichimura S, Hayakawa M, Arai H, Maruo Y, Kusaka T, et al. Neonatal jaundice in preterm infants with bilirubin encephalopathy. Neonatology. 2021;118(3):301-9. [DOI:10.1159/000513785]

7. Chang PW, Newman TB. A Simpler Prediction Rule for Rebound Hyperbilirubinemia. Pediatrics. 2019;144(1). [DOI:10.1542/peds.2018-3712]

8. Faulhaber FR, Procianoy RS, Silveira RC. Side effects of phototherapy on neonates. American journal of perinatology. 2019;36(03):252-7. [DOI:10.1055/s-0038-1667379]

9. Niknafs N, Nili F, Dalili H, Nayeri F, Esmaeilnia T, Amini E. A comparison of significant bilirubin rebound after discontinuation of phototherapy in two groups of neonates in Valiasr Hospital: a randomized clinical trial. Iranian Journal of Neonatology IJN. 2014;4(4):17-21.

10. Kaplan M, Kaplan E, Hammerman C, Algur N, Bromiker R, Schimmel MS, et al. Post-phototherapy neonatal bilirubin rebound: a potential cause of significant hyperbilirubinaemia. Archives of disease in childhood. 2006;91(1):31-4. [DOI:10.1136/adc.2005.081224]

11. Erdeve O, Tiras U, Dallar Y. Rebound bilirubin measurement is not required for hyperbilirubinemia regardless of the background attributes of newborns. Journal of Tropical Pediatrics. 2004;50(5):309 [DOI:10.1093/tropej/50.5.309]

12. Maisels MJ, Kring E. Rebound in serum bilirubin level following intensive phototherapy. Archives of pediatrics & adolescent medicine. 2002;156(7):669-72. [DOI:10.1001/archpedi.156.7.669]

13. Boskabadi H, Zakerihamidi M, Bagheri F. Frequency of major and minor risk factors associated with jaundice in hospitalized newborns. Tehran University Medical Journal. 2017;75(2):141-51.

14. Jangaard KA, Vincer MJ, Allen AC. A randomized trial of aggressive versus conservative phototherapy for hyperbilirubinemia in infants weighing less than 1500 g: short-and long-term outcomes. Paediatrics & child health. 2007;12(10):853-8.

15. Kaplan M, Bromiker R, Schimmel M, Algur N, Hammerman C. Evaluation of discharge management in the prediction of hyperbilirubinemia: the Jerusalem experience. The Journal of Pediatrics. 2007;150(4):412-7. [DOI:10.1016/j.jpeds.2006.12.014]

16. Abd-Ellatif MAK, Abd-Ellatif DAK. The use of intensive phototherapy in severe neonatal hyperbilirubinemia. Journal of the Egyptian Society of Parasitology. 2012;240(1410):1-11. [DOI:10.12816/0006334]

17. Muchowski KE. Evaluation and treatment of neonatal hyperbilirubinemia. American family physician. 2014;89(11):873-8.

18. Elhawary IM, Abdel Ghany EAG, Aboelhamed WA, Ibrahim SGE. Incidence and risk factors of post-phototherapy neonatal rebound hyperbilirubinemia. World Journal of Pediatrics. 2018;14(4):350-6. [DOI:10.1007/s12519-018-0119-9]

19. Almohammadi H, Nasef N, Al-Harbi A, Saidy K, Nour I. Risk Factors and Predictors of Rebound Hyperbilirubinemia in a Term and Late-Preterm Infant with Hemolysis. American Journal of Perinatology. 2020;29. [DOI:10.1055/s-0040-1718946]

20. Josediputra ALC, Utomo MT, Etika R. Risk Factors of Rebound Hyperbilirubinemia in Post Phototherapy Hyperbilirubinemia Infants. Indian Journal of Forensic Medicine & Toxicology. 2021;15(4). [DOI:10.37506/ijfmt.v15i4.16774]